<DOC>
	<DOCNO>NCT02933762</DOCNO>
	<brief_summary>The primary purpose study investigate effect JNJ-54175446 ( dose response ) level Aβ fragment ( Aβ1-42 , Aβ1-40 , Aβ1-38 , Aβ1-37 ) plasma cerebrospinal fluid ( CSF ) , effect JNJ-54175446 marker ( neuro ) inflammation/protection blood CSF pharmacokinetics JNJ-54175446 follow single multiple dose administration .</brief_summary>
	<brief_title>A Study Healthy Participants Evaluate Effect JNJ-54175446 Amyloid Biomarkers Cytokine Profiles Cerebrospinal Fluid Plasma</brief_title>
	<detailed_description />
	<criteria>Participants must body mass index ( BMI ) 18 32 kilogram ( kg ) / meter ( ) ^2 , inclusive ( BMI = weight/height^2 ) Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) Part 1 2 ( Elderly Participants ) : Healthy male female participant 55 75 year age , inclusive Participant must healthy basis physical neurological examination perform Screening admission clinical unit Part 1 ( Young Participants ) : Healthy male participant 18 45 year age , inclusive Participant history current liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance , inflammatory illness illness Investigator considers exclude participant Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease , test positive HBsAg antiHCV Screening ( per Screening evaluation ) Participant history human immunodeficiency virus ( HIV ) antibody positive , test positive HIV Screening ( per Screening evaluation ) Participant history malignancy within 5 year Screening Participant sign increase intracranial pressure base fundoscopy Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>